Clinical trial Recruiting at 1 site Interventional Ages 18 and up Women only

Using a 24-hour continuous glucose monitor after delivery to predict future Type 2 diabetes risk in people with gestational diabetes

Official title: Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial

Run by University of California, Los Angeles · NCT07449039 · Data updated 2026-11-12

This pilot tests whether wearing a continuous glucose monitor for 24 hours immediately after delivery can help predict later Type 2 diabetes risk in people who had gestational diabetes.

Quick facts

Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment50 (estimated)
SponsorUniversity of California, Los Angeles
Academic / other
Locations1 site (Los Angeles, California)
StatusRecruiting
StartedSeptember 28, 2025
Main results expectedDecember 2029
Study endsJune 2030
Registry record updatedMarch 4, 2026
Trial IDNCT07449039 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults (≥18 years) with gestational diabetes who receive prenatal care and plan to deliver at UCLA Ronald Reagan or UCLA Santa Monica and who do not have pre-existing diabetes or other listed exclusions.

Probably not a fit

People with pre-gestational diabetes, multifetal pregnancies, certain infections or skin conditions at the sensor site, recent steroid/terbutaline or metformin use, or those not delivering at UCLA are not likely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center pilot enrolls people with a confirmed gestational diabetes diagnosis who receive prenatal care and plan delivery at UCLA. Participants will have a continuous glucose monitor applied within two hours after delivery, wear it for 24 hours, and remove it themselves. Two brief surveys about the device experience and health will be completed at 1–3 months and again at 12–14 months postpartum. The study excludes people with pre-gestational diabetes, multifetal gestation, recent steroid or terbutaline use, certain medical conditions, or planned postpartum imaging, and it is designed to test feasibility and early predictive signal rather than provide diagnosis or treatment.

Why it matters

Potential benefit: If successful, this approach could offer a simple, immediate way to identify people at higher risk of developing Type 2 diabetes so they can get earlier monitoring or prevention efforts.

How similar studies have gone: Continuous glucose monitoring has been used in pregnancy and postpartum settings to detect abnormal glucose patterns, but using immediate postpartum 24-hour CGM specifically to predict long-term Type 2 diabetes risk is a novel, early-stage approach with limited prior evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Prenatal care at UCLA Health
* Planning to deliver at UCLA Ronald Reagan or UCLA Santa Monica
* Confirmed gestational diabetes diagnosis based on 2-step approach
* Maternal age \>= 18 years

Exclusion Criteria:

* Pre-gestational diabetes (T1DM or T2DM)
* Multifetal gestation
* Intra-amniotic infection by clinical criteria
* Postpartum hemorrhage
* Maternal ICU admission
* Known allergy to medical-grade adhesive
* Presence of skin lesions at anticipated CGM application site
* Scheduled postpartum non-sonographic imaging study (radiograph, magnetic resonance imaging (MRI), or computed tomography (CT) scan) during trial
* Metformin use
* Steroid use
* Terbutaline use within 4 hours of delivery
* Cystic fibrosis
* MODY (mature onset of diabetes in the young)

Where it's running

  • University of California, Los Angeles
    Los Angeles, California, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.